CBL and neoplasm: Additionally, phase 1b cohorts were analyzed by diagnosis (RCC or CRPC) or by identification of a tumor molecular alteration of interest (gene amplification, mutation or rearrangement involving MET, AXL, RET, NTRK, DDR2, KDR, PDGFRA, KIT or CBL gene loci).